INSPIRIS RESILIA Aortic Valve (11500A), KONECT RESILIA Aortic Valve Conduit (AVC) (11060A), MITRIS RESILIA Mitral Valv
Edwards Lifesciences, LLC · Decision date Oct 28, 2026
What did the FDA decide?
The FDA record for P150048/S104 is a 30-day notice supplement, reason listed as process change affecting manufacturer, sterilizer, packager or supplier. The reported purpose is implementing an alternative supplier of a chemical manufacturing aid, linked to the INSPIRIS RESILIA aortic valve (11500A), KONECT RESILIA aortic valve conduit (AVC) (11060A) and MITRIS RESILIA mitral valve under product code LWR.
The identifier P150048 places this change within the existing PMA for the Edwards Lifesciences devices named, but the decision is a supplement, not a new approval of the whole system. The record does not identify the chemical aid, name either supplier, describe the manufacturing step, or give data on device safety or clinical performance. The purpose is reported by the applicant in the source statement and is not independent proof of safety or effectiveness.
The record carries decision code OK30 dated 2026-10-28, giving no further grounds for the decision.
FDA approval order statement
implementing an alternative supplier of a chemical manufacturing aid
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150048/S104
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- LWR
- Decision code
- OK30
- Decision date
- Oct 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: heart-valve, non-allograft tissue.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- LWR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150048. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150048 · Original PMA
EDWARDS PERICARDIAL AORTIC BIOPROSTHESIS (MODEL 11000A) and EDWARDS INSPIRIS RESILIA AORTIC VALVE (MODEL 11500)
P150048/S104 received
Application receipt date recorded by FDA.
P150048/S100 · Related supplement
INSPIRIS RESILIA Aortic Valve; MITRIS RESILIA Mitral Valve
P150048/S104 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P150048. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150048
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Jun 29, 2017 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code LWR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EDWARDS INTUITY Elite Valve System (8300AB)P150036/S081 | Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 18, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA approval | Aug 12, 2016 | FDA | |
| ABBOTT MEDICAL | PMA approval | Aug 5, 2005 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P150048/S104
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records